Treprostinil Diolamine

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H34O5.C4H11NO2
Molecular Weight	495.6487
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCNCCO.CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2CC3=C(OCC(O)=O)C=CC=C3C[C@H]12

InChI

InChIKey=RHWRWEUCEXUUAV-ZSESPEEFSA-N

InChI=1S/C23H34O5.C4H11NO2/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25;6-3-1-5-2-4-7/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27);5-7H,1-4H2/t16-,17-,18+,19-,21+;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C4H11NO2
Molecular Weight	105.1356
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C23H34O5
Molecular Weight	390.5131
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=27286723
Curator's Comment: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412595/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515411/

Treprostinil (marketed under the trade names Remodulin for infusion) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed. Treprostinil had high affinity for the Prostaglandin D2 receptor (DP1), Prostaglandin E2 receptor EP2 subtype (EP2) and Prostaglandin D2 receptor (IP) receptors (Ki 4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, Prostaglandin F (FP) and thromboxane (TP) receptors. Treprostinil has demonstrated a unique effect on PPAR gamma, a transcription factor important in vascular pathogenesis as a mediator of proliferation, inflammation and apoptosis. Through a complementary, yet cyclic AMP-independent pathway, treprostinil activates PPARs, another mechanism that contributes to the anti-growth benefits of the prostacyclin class.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Prostanoid IP receptor 19 Target ID: CHEMBL1995 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18574748	Agonist 2752	32.0 nM [Ki]
Prostanoid DP receptor 16 Target ID: CHEMBL4427 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22480736	Agonist 2752	4.4 nM [Ki]
Prostanoid EP2 receptor 20 Target ID: CHEMBL1881 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22480736	Agonist 2752	3.6 nM [Ki]
Peroxisome proliferator-activated receptor delta 30 Target ID: CHEMBL3979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16239641	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pulmonary arterial hypertension 36 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021272s009lbl.pdf	Primary		Approved 8583	REMODULIN Approved Use Remodulin is a prostacyclin vasodilator indicated for: Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) (1.1) Patients who require transition from Flolan®, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. (1.2) 1.1 Pulmonary Arterial Hypertension Remodulin is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) [see Clinical Studies (14.1) Launch Date 2002

C_max

Value	Dose	Co-administered	Analyte	Population
0.54 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		TREPROSTINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.71 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117	0.5 mg 3 times / day multiple, oral dose: 0.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TREPROSTINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
2.46 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		TREPROSTINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.53 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117	0.5 mg 3 times / day multiple, oral dose: 0.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TREPROSTINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:		TREPROSTINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24603117	0.5 mg 3 times / day multiple, oral dose: 0.5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TREPROSTINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
9% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021272s020lbledt.pdf			TREPROSTINIL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
20 mg 3 times / day steady, subcutaneous Overdose Dose: 20 mg, 3 times / day Route: subcutaneous Route: steady Dose: 20 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19285625/	unhealthy, 10 years Health Status: unhealthy Age Group: 10 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/19285625/	Disc. AE: Nausea, Blurred vision... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Blurred vision (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/19285625/
7.5 mg single, subcutaneous Overdose Dose: 7.5 mg Route: subcutaneous Route: single Dose: 7.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/29674328/	unhealthy, 29 years Health Status: unhealthy Age Group: 29 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/29674328/	Disc. AE: Circulatory collapse... AEs leading to discontinuation/dose reduction: Circulatory collapse (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29674328/
150 ug single, respiratory Highest studied dose Dose: 150 ug Route: respiratory Route: single Dose: 150 ug Sources: https://pubmed.ncbi.nlm.nih.gov/33282202/	healthy, 30.3 years Health Status: healthy Age Group: 30.3 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/33282202/	Other AEs: Cough, Throat irritation... Other AEs: Cough (26 patients) Throat irritation (26 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/33282202/
100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/	unhealthy, 58 years Health Status: unhealthy Age Group: 58 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/	Disc. AE: Hypotension, Tachycardia... AEs leading to discontinuation/dose reduction: Hypotension (1 patient) Tachycardia (1 patient) Arrhythmia ventricular (1 patient) Dyspnea (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/
36 ug 4 times / day steady, respiratory Recommended Dose: 36 ug, 4 times / day Route: respiratory Route: steady Dose: 36 ug, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22917554/	unhealthy, 7.1 - 19.2 years Health Status: unhealthy Age Group: 7.1 - 19.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22917554/	Disc. AE: Bronchospasm... AEs leading to discontinuation/dose reduction: Bronchospasm (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22917554/

AEs

AE	Significance	Dose	Population
Blurred vision	1 patient Disc. AE	20 mg 3 times / day steady, subcutaneous Overdose Dose: 20 mg, 3 times / day Route: subcutaneous Route: steady Dose: 20 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19285625/	unhealthy, 10 years Health Status: unhealthy Age Group: 10 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/19285625/
Nausea	1 patient Disc. AE	20 mg 3 times / day steady, subcutaneous Overdose Dose: 20 mg, 3 times / day Route: subcutaneous Route: steady Dose: 20 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19285625/	unhealthy, 10 years Health Status: unhealthy Age Group: 10 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/19285625/
Circulatory collapse	1 patient Disc. AE	7.5 mg single, subcutaneous Overdose Dose: 7.5 mg Route: subcutaneous Route: single Dose: 7.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/29674328/	unhealthy, 29 years Health Status: unhealthy Age Group: 29 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/29674328/
Cough	26 patients	150 ug single, respiratory Highest studied dose Dose: 150 ug Route: respiratory Route: single Dose: 150 ug Sources: https://pubmed.ncbi.nlm.nih.gov/33282202/	healthy, 30.3 years Health Status: healthy Age Group: 30.3 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/33282202/
Throat irritation	26 patients	150 ug single, respiratory Highest studied dose Dose: 150 ug Route: respiratory Route: single Dose: 150 ug Sources: https://pubmed.ncbi.nlm.nih.gov/33282202/	healthy, 30.3 years Health Status: healthy Age Group: 30.3 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/33282202/
Arrhythmia ventricular	1 patient Disc. AE	100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/	unhealthy, 58 years Health Status: unhealthy Age Group: 58 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/
Dyspnea	1 patient Disc. AE	100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/	unhealthy, 58 years Health Status: unhealthy Age Group: 58 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/
Hypotension	1 patient Disc. AE	100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/	unhealthy, 58 years Health Status: unhealthy Age Group: 58 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/
Tachycardia	1 patient Disc. AE	100 mg single, subcutaneous Overdose Dose: 100 mg Route: subcutaneous Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/	unhealthy, 58 years Health Status: unhealthy Age Group: 58 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/23662045/
Bronchospasm	3 patients Disc. AE	36 ug 4 times / day steady, respiratory Recommended Dose: 36 ug, 4 times / day Route: respiratory Route: steady Dose: 36 ug, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22917554/	unhealthy, 7.1 - 19.2 years Health Status: unhealthy Age Group: 7.1 - 19.2 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22917554/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inducer 1087	substrate 1193 inducer 440	substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C8 810 CYP1A2 1197 CYP2A6 626 CYP2C19 1119 CYP4A11 137	CYP1A2 832 CYP2B6 669 CYP2C19 329

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP2C19 2141	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page=13 Page: 13.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12,14	major	yes (co-administration study) Comment: Treprostinil plasma AUC and Cmax increased approximately 2-fold when administered with gemfibrozil; Treprostinil AUC decreased by 30% when adminsitered with rifampin; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12,14
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12,14	minor	weak (co-administration study) Comment: Treprostinil AUC decreased approximately 14%, no effect on Cmax when adminstered with fluconazole; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12,14
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12.0	no
CYP2A6 626	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12.0	no
CYP4A11 137	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000ClinPharmR.pdf#page12 Page: 12.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022387s000PharmR.pdf#page=7 Page: 7.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:50861	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50861
ChemicalBook	CB32460050	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32460050
MolPort	MolPort-027-720-928	https://www.molport.com/shop/molecule-link/MolPort-027-720-928
ZINC	ZINC000003800475	http://zinc15.docking.org/substances/ZINC000003800475

PubMed

Title	Date	PubMed
Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.	2012-07-01	22480736
Inhaled treprostinil and pulmonary arterial hypertension.	2010-12-03	21191432
The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results.	2010-11	22043212
Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.	2010-07-23	20522807
Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan.	2010-06	20584221
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.	2010-05-04	20430262
Gateways to clinical trials.	2010-05	20508873
The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.	2010-03-04	20209098
Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.	2010-01-29	20113497
Gateways to clinical trials.	2009-09	19907722
Primary pulmonary hypertension as a manifestation of adult multi-system mitochondrial disorder.	2009-04-30	19430571
A novel catheter system for totally implantable intravenous drug therapy: assessment of catheter function and patency with trepostinil therapy.	2008-04-02	18379976
Patient safety challenges in treprostinil therapy.	2008-04	18517170
Treatment of a nonhealing saphenous vein harvest graft with treprostinil sodium.	2008-04	18355483
Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.	2008-01	18094217
Treprostinil for pulmonary hypertension.	2008	18827901
Gateways to clinical trials.	2007-11	18193114
IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues.	2007-09-07	17624303
Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.	2007-03-02	17332729
The Role of PPARs in Lung Fibrosis.	2007	17710235
The role of peroxisome proliferator-activated receptors in pulmonary vascular disease.	2007	17710111
Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study.	2006-09-08	16956486
Gateways to clinical trials.	2006-09	17003851
Gateways to clinical trials.	2006-08-09	16894408
Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.	2006-06	16778286
Gateways to clinical trials.	2006-03-17	16541195
Gateways to clinical trials.	2006-03	16636723
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.	2006-02	16239641
The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease--a case report and review of literature.	2006-01-31	16444463
[The best of clinical cardiovascular pharmacology in 2005].	2006-01	16479971
Gateways to clinical trials.	2005-12	16395422
Gateways to clinical trials.	2005-09	16258596
Gateways to clinical trials.	2005-06	16082422
Gateways to clinical trials.	2005-04-19	15834459
Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.	2005-04	15755791
Gateways to clinical trials.	2004-09-07	15349141
Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers.	2004-08	15243302
Gateways to clinical trials.	2004-06	15319815
Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.	2004-05	15102871
Treprostinil for pulmonary hypertension.	2004-03	15151467
Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.	2004-03	15148531
Gateways to clinical trials.	2004-03	15071612
Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.	2004-01	14681345
Gateways to clinical trials.	2003-09	14571286
Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents.	2003-05-01	12756943
Gateways to clinical trials.	2002-12	12616965
Treprostinil sodium Pharmacia.	2002-04	12090728

Patents

Sample Use Guides

In Vivo Use Guide

1.25 ng/kg/min (initial dose for continuous infusion, dosage should be chronically adjusted depending on clinical response)

Route of Administration: Other

In Vitro Use Guide

Treprostinil (0.15 - 15 ng/ml) rat cardiomyocytes

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:16:51 GMT 2025` Edited by `admin` on `Mon Mar 31 20:16:51 GMT 2025`
Record UNII	H1FKG90039
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Acetic acid, [[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]-, compd. with 2,2?-iminobis[ethanol] (1:1)

Preferred Name

English

Treprostinil Diolamine

Official Name

English

ORENITRAM

Brand Name

English

TREPROSTINIL DIETHANOLAMINE

Common Name

English

Treprostinil diolamine [WHO-DD]

Common Name

English

TREPROSTINIL DIOLAMINE [ORANGE BOOK]

Common Name

English

Acetic acid, 2-[[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]-, compd. with 2,2?-iminobis[ethanol] (1:1)

Systematic Name

English

UT-15C

Code

English

TREPROSTINIL DIOLAMINE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C78568